<DOC>
	<DOC>NCT02398955</DOC>
	<brief_summary>Biomime stent is a novel sirolimus-eluting stent (SES) (Meril Life Sciences Pvt. Ltd., Gujarat, India) with an ultra-thin stent platform (65 Î¼m) and a biodegradable polymer licensed for the treatment of de novo coronary lesions. However no data regarding the efficacy and safety of this stent in an "all-comers" patient population treated with percutaneus coronary interventions (PCI) have been published so far. In this registry the investigators aimed to collect clinical and angiographic information about an extensive "all-comers" employ of this novel stent.</brief_summary>
	<brief_title>Biomime Stent in All-comers PCI Patients Registry</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>any coronary artery disease treated with percutaneous coronary intervention and a Biomime stent patients &lt;18 years old</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Drug-Eluting Stents</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Absorbable Implants</keyword>
</DOC>